Deepali S Jankar¹ , Kanchan C Wingkar¹ , Ajit V Sontakke²  and Chintamani D Bodhe^3*

¹Department of Physiology, KIMS, Karad, India, 415539

²Department of Biochemistry, KIMS, Karad, India, 415539

³Department of Physiology, GMC, Miraj, Idida, 416410.

Corresponding  Author E-mail: drchintamani14@gmail.com

DOI : https://dx.doi.org/10.13005/bpj/2295

Abstract

Introduction:- Vitamin D has been studied as modifiable risk factor in DM. Apart from its role in glucose homeostasis, the anti-inflammatory effect of vitamin D is claimed to have important effect on beta cell survival and on hepatic cells. Vitamin D is said to have anti-inflammatory, anti-proliferative and anti-fibrotic actions in liver. VDD is more prevalent in T2DM, obese and NAFLD even when these conditions occur separately. Literature states the protective effective of vitamin D on kidney. Association of VDD with albuminuria and chronic kidney disease in diabetics has also been reported. Material and Methods:- This is a type of comparative and interventional study. 63 T2DM patients aged 30 – 60 years with VDD were included. Baseline investigations determined blood levels of vitamin D, calcium, phosphate, liver enzymes (AST, ALT, ALP) and serum creatitine. Patients received vitamin D intervention orally in the dose of 2000 IU daily for 12 weeks. After 12 weeks blood levels of vitamin D, calcium, phosphate, liver enzymes (AST, ALT, ALP) and serum creatitine were determined. Results:- There was no correlation of vitamin D with urea, creatinine, calcium, phosphate, AST, ALT and ALP. There was extremely significant rise in vitamin D, significant fall in phosphate level, non-significant fall in creatinine, AST, ALT, ALP and non-significant rise in calcium, urea after 12 weeks of vitamin D supplementation. Conclusion:- There was no correlation of vitamin D with hepatic and renal parameters. Also 12 weeks of vitamin D supplementation had no significant improvement in these parameters in T2DM.

Keywords

Endocrine; Hepatic; Kidney; Metabolism; Nutrition;

Download this article as: 

Copy the following to cite this article: Jankar D. S, Wingkar K. C, Sontakke A. V, Bodhe C. D. Study of Effect of Vitamin D Supplementation on Selected Hepatic and Renal Parameters in T2DM with Vitamin D Deficiency. Biomed Pharmacol J 2021;14(4)

Copy the following to cite this URL: Jankar D. S, Wingkar K. C, Sontakke A. V, Bodhe C. D. Study of Effect of Vitamin D Supplementation on Selected Hepatic and Renal Parameters in T2DM with Vitamin D Deficiency. Biomed Pharmacol J 2021;14(4). Available from: https://bit.ly/3mcPWoL

Introduction

Diabetes mellitus (DM) per se is caused by decreased insulin secretion and/or increased insulin resistance. However, genetic and environmental factors play important role in its progression.¹ Nutrient deficiency, stress, physical inactivity, obesity are some modifiable risk factors associated with DM. ² Though medical therapy of DM achieves glycemic control over short term to medium term, eventually it progresses to beta cell failure and loss of glycemic control.³ Also DM in the long run leads to several microvascular and macrovascular complications.¹ Type II diabetes mellitus (T2DM) prevalence in 2019 was 463 million adults worldwide and 77 million adults in India. The prevalence in India is expected to rise to 101 million by 2030. ⁴ This puts tremendous burden on the family, society and economy.¹

Vitamin D has been studied as modifiable risk factor in DM. This is because several researchers have mentioned the association of vitamin D deficiency (VDD) with decreased insulin secretion, increased insulin resistance and blood glucose level. ^2,5 Apart from its role in glucose homeostasis, the anti-inflammatory effect of vitamin D is claimed to have important effect on beta cell survival and on hepatic cells.^1,6

The prevalence of non-alcoholic fatty liver disease (NAFLD) is reported to be 90% in obese T2DM and 20% in general population. NAFLD in T2DM is said to be associated with increased Insulin resistance (IR), deteriorated metabolism and increased micro and macro-angiopathies. Like NAFLD, VDD is also more prevalent in obese T2DM. In fact, it is said that NAFLD increases the risk of VDD by 26%. Diabetes can accelerate NAFLD resulting in liver damage and its complications.⁶

VDR are expressed in hepatic cells. VDD and vitamin D receptor (VDR) expression is associated with chronic inflammatory injury to liver. Vitamin D is said to have anti-inflammatory, anti-proliferative and anti-fibrotic actions in liver. VDD is more prevalent in T2DM, obese and NAFLD even when these conditions occur separately. ⁶

Though there are separate studies on occurrence of Vitamin D Deficiency in NAFL or VDD in T2DM or NAFLD in T2DM, the number of studies exploring the relation of vitamin D in liver damage in T2DM is quite limited. Therefore we proposed this study to determine the relation of vitamin D with parameters of liver damage in T2DM and the effects of vitamin D supplementation on these parameters.

Literature states the protective effective of vitamin D on kidney. Association of VDD with albuminuria and chronic kidney disease in diabetics has also been reported. ⁷ However the number of studies on VDD and renal function and effect of vitamin D supplementation on renal function are quite limited. Therefore we proposed this study to determine the relation of vitamin D with selected parameters of renal function in T2DM and the effects of vitamin D supplementation on these parameters.

Aim and Objectives

Aim

To study the effects of vitamin D supplementation on selected liver and renal parameters in type II diabetic patients with VDD

Objectives

To study the selected liver and renal parameters in T2DM patients with VDD

To study the selected liver and renal parameters after 12 weeks of vitamin D supplementation.

To find the association of vitamin D with selected liver and renal parameters.

Material and Methods

The present study was approved by the Institutional Ethics Committee. This is a type of comparative and interventional study (before and after). 63 T2DM patients aged 30 – 60 years with VDD and on oral hypoglycemic willing to participate in the study were included. Patients with T1DM, T2DM on insulin or having cardiovascular, neural, thyroid, renal or liver complications and metabolic diseases (Paget’s disease or osteomalacia), hyperparathyroidism, renal stone disease were excluded. Informed written consent was obtained after explaining the study procedure. Research fund allotment committee approved the funding for the project.

Baseline investigations were done to determine blood levels of vitamin D, Calcium and Phosphate, liver enzymes (AST, ALT, ALP) and Serum Creatitine. Patients received vitamin D intervention orally in the dose of 2000 IU daily for 12 weeks. Compliance to the supplementation was also supervised by research worker once a week by telephonic conversation with the patient. During study period, antidiabetic medication of patients was continued as usual & patients were advised to maintain their normal diet & continue their habitual physical activity. After 12 weeks blood levels of vitamin D, Calcium and Phosphate, liver enzymes (AST, ALT, ALP) and Serum Creatitine were determined.

Venous blood sample was collected after an overnight fast by using disposable needles and syringes. After two hours, the samples were centrifuged at 3000 RPM for 5 minutes, serum from plain blood and plasma from anticoagulated blood were separated.

Estimation of vitamin D

vitamin D was done by Enzyme Immunoassay. ⁸ 25- OH vitamin D is a better indicator of status of vitamin D in the body though biologically active form is 1, 25- OH vitamin D. The ST AIA- PACK 25- OH vitamin D is a one step delayed competitive enzyme immunoassay done on TOSOH autoanalyzer.

Test cups contain lyophilized twelve magnetic beads coated with anti-25-OH vitamin D sheep monoclonal antibody with sodium azide as a preservative. Vitamin D Conjugate contains vials with liquid 25- OH vitamin D conjugated to bovine alkaline phosphatase. Before actual determination of vitamin D, first serum was pretreated with the pretreatment reagent containing sodium hydroxide which dissociates 25-OH vitamin D from its binding proteins. During first incubation, 25- OH vitamin D from the pretreated sample is bound to 25- OH vitamin D specific monoclonal antibody immobilized on magnetic beads. In this test enzyme labeled 25-OH vitamin D was added to the reaction mixture which competes with the 25- OH vitamin D for binding to antibody on magnetic beads in the reaction mixture. The magnetic beads are washed to remove unbound enzyme labeled 25- OH vitamin D during second incubation and then incubated with 4MUP which is a flurogenic substrate.

25- OH vitamin D in the test sample is inversely related to the amount of enzyme labeled

25- OH vitamin D that binds to the beads. The machine constructs a standard curve and unknown vitamin D concentration was calculated.

The values obtained have units in ng/ml.

Estimation of Calcium and Phosphate were done by standard method on autoanalyser. ⁹

Determination of Calcium – Principle:- A colored chromophore is formed at pH 6.5 when calcium and Arsenazo II are combined. The absorbance is measured at 650 nm which is proportional to calcium concentration.

Determination of Phosphate – Principle Inorganic phosphorus and ammonium molybdate combines to form phosphomolybdate in the presence of strong acids. This phosphomolybdate is directly proportional to the inorganic phosphorus when measured at 340 nm.

Estimation of liver enzymes (AST, ALT, ALP)

Estimation of liver enzymes (AST, ALT, ALP) was done by standard method. ¹⁰

Determination of AST

AST in the sample transfers amino group from L- aspartate to 2- oxoglutarate forming oxaloacetate and L-glutamate. Malate Dehydrogenase (MDH) reduces oxaloacetate in the presence of NADH to L- malate and NAD. Oxidation of NADH to NAD is monitored by measuring rate of decrease in absorbance at 340nm. Complete and rapid reduction of endogenous pyruvate is necessary to avoid interference in the reaction which is done by LDH (Lactate Dehydrogenase) added to the reagent.

Determination of ALT

The amino group from alanine is transferred enzymatically to the carbon atom of 2-oxoglutarate forming pyruvate and L- glutamate. Pyruvate is then reduced by LDH present in the reagent to lactate causing simultaneous oxidation of NADH to NAD. The rate of decrease in absorbance due to NADH oxidation is measured at 340 nm. To avoid interference during the assay endogenous sample pyruvate is rapidly and completely reduced by LDH during initial incubation.

Determination of Alkaline Phosphatase

4-nitrophenol is used as substrate. At alkaline pH, 4-nitrophenol has an intense yellow color. In the reagent, to maintain the optimal concentration of zinc and magnesium a metal ion buffer system is present. This buffer system can chelate other potentially inhibitor ions. ALP concentration in the serum is directly proportional to the rate of increase in the absorbance at 415 nm.

Estimation of Serum Creatitine

Estimation of Serum Creatitine was done by using Creatinine Reagent (Modified Jaffe’s reaction) by a standard method. ¹¹

Principle- Creatinine produces red colored reaction (Jaffe reaction) when combines with alkaline picrate. Kinetic method has improved the specificity of the tests as many substances can give this non specific reaction.

Estimation of Serum Urea

Estimation of Serum Urea was done by using Urea Reagent by a standard method.

Principle:- Urease hydrolyses urea in the presence of water and forms ammonia and carbon dioxide. Ammonia and NADH combines in the presence of GLDH (Glutamate Dehydrogenase) and α- keto glutarate to form L- glutamate. As NADH is converted to NAD, the reaction is monitored at 340 nm by measuring rate of decrease in absorbance. 

Statistical Analysis

Instat 3 software was used for statistical analysis. Correlation of the parameters at baseline with vitamin D in was done by Pearson correlation. Parameters before and after intervention in were compared by paired t test.

Results

Study group (n=63)

Age group:-50.4 ± 6.20

Sex:- Male: Female 34:29

Table 1: comparison of parameters Before and After vitamin D supplementation.

Parameter	Mean ± SD		P value	Significance
	Before	After
Vitamin D	14.79 ± 3.64	17.89 ± 4.42	< 0.0001	Extremely  significant
Calcium	8.75 ± 1.17	9.02 ± 1.06	0.2049	Not significant
Phosphorus	3.44 ± 1.05	3.02 ± 0.66	0.0103	Significant
Urea	23.53 ± 8.72	24.01 ± 6.59	0.7213	Not significant
Creat	1.13 ± 0.18	1.11 ± 0.19	0.6921	Not significant
SGOT	24.61 ± 12.07	24.52 ± 8.63	0.9614	Not significant
SGPT	24.84 ± 12.33	24.82 ± 10.74	0.9932	Not significant
Alk Phosphatse	85.39 ± 31.45	84.53 ± 19.75	0.8635	Not significant

Table 1 shows extremely significant rise in vitamin D, significant fall in phosphate level, non-significant fall in creatinine, AST, ALT, ALP and non-significant rise in calcium, urea after 12 weeks of vitamin D supplementation.

Table 2: Baseline correlation of parameters with Vitamin D.

Parameter	r	r squared	P value	Significance
Calcium	-0.09327	0.008699	0.4672	Not significant
Phosphorus	0.1304	0.01699	0.3085	Not significant
Urea	0.2439	0.05948	0.0541	Not significant
Creat	-0.01884	0.0003549	0.8835	Not significant
SGOT	0.07746	0.006001	0.5462	Not significant
SGPT	0.0801	0.006416	0.5326	Not significant
Alk Phosphatse	0.113	0.01277	0.3779	Not significant

Table 2 shows no correlation of vitamin D with urea, creatinine, calcium, phosphate, AST, ALT and ALP.

Discussion

We found a significant increase in the blood vitamin D level after 12 weeks of vitamin D supplement but failed to achieve normal level of 20 ng/ml. Similar findings have been reported by Ivan Al-Shahwan MA, et al,² A Sadiya et al, ⁵ Parini Patel, et al¹² and Al-Daghri NM, et al. ¹³ 

The probable causes are – inadequate dose and/or duration of vitamin D, ethnic differences and less bioavailability of vitamin D. ⁵

Vitamin D and Liver Enzymes

There was no correlation of vitamin D with AST, ALT and ALP at baseline. On 12 weeks of vitamin D supplementation there was non-significant fall AST, ALT and ALP.

Ravindra Shukla et al¹⁴ reported significant rise in ALP in diabetics. İlker Boyraz et al¹⁵ reported normal AST and ALT levels in T2DM patients.

Amena Sadiya et al¹⁶ reported negative relationship of vitamin D with ALP. Ahern T et al¹⁷ reported no associations of vitamin D with ALP. Luo C et al¹⁸ reported no association of vitamin D with AST.

Conghua Ning et al¹⁹ reported extremely elevated AST and ALT in diabetic rats at baseline and reported significant reduction in AST and ALT following vitamin D supplementation. Luo C et al¹⁸ reported no significant change in liver enzymes after vitamin D supplementation. Nwosu BU et al²⁰ reported a significant decrease in ALT following vitamin D supplementation. Barchetta I et al⁶ and Ryu OH et al²¹ reported no significant changes in AST, ALT after vitamin D supplementation. Leonardo M. Bella et al²² reported no significant difference in AST, ALT and ALP levels in diabetic mice even after vitamin D supplementation.

AST (SGOT) and ALT (SGPT) are commonly used and most sensitive markers of liver injury. Normal serum levels of AST and ALT are 5- 35 IU/lit and 0-40 IU/lit respectively. ¹⁰ One disadvantage of using aminotransferases as markers of liver injury is that their levels do not  correspond with the extent of liver damage. Also they cannot be used for prognostic purpose. ²³

Normal serum ALP levels are 37-147 Iu/lit. ¹⁰ ALP increases in liver injury. But ALP also increases with increased new bone formation. ¹⁴ Thus, expertise is required to interpret alterations in ALP together with clinical correlation.

VDR are expressed on all hepatocytes. Vitamin D exerts its anti-inflammatory, antiproliferative and antifibrotic effect by direct action. Also it increases free fatty acid uptake by its insulin sensitizing effect on hepatocytes. ⁶ Raised serum transaminases levels indicate hepatic  dysfunction. Thus decreased transaminases levels towards normal signify improvement in hepatic function. ^6,20

The aminotranseferse and ALP levels in our participants were fairly within normal range. It may be because of the fact that we included T2DM without any complications. Inclusion of T2DM with clinical findings of liver injury may reflect alterations in aminotransferases and ALP. Also correction of vitamin D level in such patients may favorably change liver function and hence levels of aminotransferases and ALP. Nevertheless, vitamin D is said to have anti-inflammatory, anti-proliferative and anti-fibrotic actions in liver. So a study with inclusion of DM with liver damage is warranted before arriving at particular conclusion.

Vitamin D and Electrolytes

There was no correlation of vitamin D with calcium and phosphate group at baseline. On 12 weeks of vitamin D supplementation there was significant fall in phosphate level and non-significant rise in Calcium.

İlker Boyraz et al²⁴ reported normal calcium and phosphate levels in T2DM patients. Alam U et al²⁵ reported marginally high calcium in vitamin D sufficient group than VDD with T2DM. Al-Shoumer et al²⁶ reported significantly lower phosphate in the patients. Conghua Ning et al¹⁹ reported no difference in calcium and phosphate levels in rats with VDD and without VDD.

Positive relationship of vitamin D with calcium was reported by Amena Sadiya et al¹⁶ and Lim S et al.²⁷ While Ahern T et al¹⁷ reported no associations of vitamin D with calcium.

Al-Daghri NM et al¹³ reported significant increase in calcium and no significant change in phosphate with 18 months vitamin D supplementation. While no significant change in calcium after vitamin D supplementation was reported by Patel P et al,¹² Ryu OH et al²¹ and Nazarian S et al. ²⁸ 

We must remember that regulation of blood calcium and phosphate levels depend not only on vitamin D but also on parathyroid hormone (PTH) and calcitonin. ²⁹ And in uncomplicated T2DM the function of these hormones and hence calcium and phosphate levels are expected to be normal.

Both Calcium and PTH can independently influence insulin release as well as peripheral insulin sensitivity. Thus both can be potential confounding factors after vitamin D supplementation. ²⁸ 

Vitamin D and Renal Parameters

There was no correlation of vitamin D with urea and creatinine at baseline. On 12 weeks of vitamin D supplementation there was non-significant rise in urea and non-significant fall in creatinine.

Cimbek A et al³⁰ reported positive correlations of vitamin D with creatinine. Amena Sadiya et al¹⁶ reported no association of vitamin D with creatinine.

No significant change in creatinine following 24 weeks vitamin D supplementation was reported by Nwosu B et al. ²⁰ 

Chronic hyperglycemia leads to increased production of advanced glycation end products (AGEs). AGEs are important in the pathogenesis of end organ damage like diabetic nephropathy, diabetic retinopathy. Vitamin D by its antioxidant and anti-inflammatory effects can decrease the accumulation of AGEs. ³¹ Vitamin D exhibits protective action on kidney through inhibition of renin angiotensin system (RAS). Also it protects kidney from inflammatory damage and fibrosis. ⁷

The strengths of the study include inclusion of T2DM patients with VDD, estimation of vitamin D with standard method, we ensure patient compliance and we did not change patients’ medications or lifestyle.

The limitations of the study include relatively small sample size, relatively small duration of the study, T2DM patients with complications were not included, HbA1c which is a good indicator of glycemic status was not estimated.

Suggestions for further studies

Studies with high doses of Vitamin D for long intervention duration in identified high risk T2DM patients should be taken. The optimum vitamin D level at which glycemic control is maximum and the ultimate vitamin D levels that cause derangement in glucose homeostasis should be identified.

Bioavailability of Vitamin D and concentration of free or active vitamin D should be given due consideration.

Conclusion

There was no correlation of vitamin D with hepatic and renal parameters. Also 12 weeks of vitamin D supplementation had no significant improvement in these parameters in T2DM.

Acknowledgement

We are grateful to KIMS, Karad for funding this project. We are thankful to the supporting staff of blood collection center and the laboratory staff for their help.

Conflict of Interest

No conflict of interest.

Funding Source

KIMS, Karad

References

1. Mitchell DM, Leder BZ, Cagliero E, Mendoza N, Henao MP, Hayden DL, Finkelstein JS, Burnett-Bowie SA. Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. Am J ClinNutr. 2015 Aug;102(2):385-92.
   CrossRef
2. Al-Shahwan MA, Al-Othman AM, Al-Daghri NM, Sabico SB. Effects of 12-month, 2000IU/day vitamin D supplementation on treatment naïve and vitamin D deficient Saudi type 2 diabetic patients. Saudi Med J. 2015 Dec;36(12):1432-8.
   CrossRef
3. Ramchandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme Shows that Lifestyle Modification and Metformin Prevent Type 2 Diabetes in Asian Indian Subjects With Impaired Glucose Tolerance (IDPP-1) Diabetologia 2006;49:289-97
   CrossRef
4. https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf
5. Sadiya A, Ahmed SM, Carlsson M, Tesfa Y, George M, Ali SH, Siddieg HH, Abusnana S. Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial. Eur J ClinNutr. 2015 Jun;69(6):707-11.
   CrossRef
6. Ilaria Barchetta, Maria Del Ben, Francesco Angelico, Michele Di Martino, Antonio Fraioli, Giuseppe La Torre, Rosella Saulle, Ludovica Perri, Sergio Morini, Claudio Tiberti, Laura Bertoccini, Flavia Agata Cimini, Francesca Panimolle, Carlo Catalano, Marco Giorgio Baroni, Maria Gisella Cavallo. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine (2016) 14:92
   CrossRef
7. Usluogullari CA, Balkan F, Caner S, Ucler R, Kaya C, Ersoy R, Cakir B. The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocr Disord. 2015 Jun 25;15:33.
   CrossRef
8. Manual of 25-OH vitamin D Enzyme Immunoassay ST AIA- PACK 25-OH vitamin D
   CrossRef
9. Manual of Erba Mannheim XL System Packs for calcium and phosphorus
   CrossRef
10. Manual of Erba Mannheim XL System Packs for AST, ALT and Alkaline phosphatase
    CrossRef
11. Manual of Erba Mannheim XL System Packs for Creatinine and Urea
    CrossRef
12. Patel P, Poretsky L, Liao E. Lack of effect of subtherapeutic vitamin D treatment on glycemic and lipid parameters in Type 2 diabetes: A pilot prospective randomized trial. J Diabetes. 2010 Mar;2(1):36-40.
    CrossRef
13. Al-Daghri NM, Alkharfy KM, Al-Othman A, El-Kholie E, Moharram O, Alokail MS, Al-Saleh Y, Sabico S, Kumar S, Chrousos GP. Vitamin D supplementation as an adjuvant therapy for patients with T2DM: an 18-month prospective interventional study. Cardiovasc Diabetol. 2012 Jul 18;11:85.
    CrossRef
14. Ravindra Shukla, Asish Kumar Basu, Biplab Mandal, Pradip Mukhopadhyay, Animesh Maity, Satyam Chakraborty, Praveen Kumar Devrabhai. 11β Hydroxysteroid dehydrogenase – 1 activity in type 2 diabetes mellitus: a comparative study. BMC Endocrine Disorders (2019) 19:15 https://doi.org/10.1186/s12902-019-0344-9
    CrossRef
15. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Ebeling PR, Daly RM. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab. 2012 Jun;97(6):1953-61.
    CrossRef
16. Amena Sadiya, Solafa M. Ahmed, Sijomol Skaria, Salah Abusnana. Vitamin D Status and Its Relationship with Metabolic Markers in Persons with Obesity and Type 2 Diabetes in the UAE: A Cross-Sectional Study. Journal of Diabetes Research Volume 20, Article ID 86930, 7 pages http://dx.doi.org/10.1155/2014/869307
    CrossRef
17. Ahern T, Khattak A, O’Malley E, Dunlevy C, Kilbane M, Woods C, McKenna MJ, O’Shea D. Association between vitamin D status and physical function in the severely obese. J Clin Endocrinol Metab. 2014 Jul;99(7):E1327-31.
    CrossRef
18. Luo C, Wong J, Brown M, Hooper M, Molyneaux L, Yue DK. VDD in Chinese type 2 diabetes: lack of impact on clinical metabolic status and biomarkers of cellular inflammation. Diab Vasc Dis Res. 2009 Jul;6(3):194-9.
    CrossRef
19. Conghua Ning, Lina Liu1, Guodong Lv, Ye Yang. Lipid metabolism and inflammation modulated by Vitamin D in liver of diabetic rats. Lipids in Health and Disease volume 14, Article number: 31 (2015)
    CrossRef
20. Nwosu BU, Maranda L. The effects of vitamin D supplementation on hepatic dysfunction, vitamin D status, and glycemic control in children and adolescents with vitamin D deficiency and either type 1 or type 2 diabetes mellitus. PLoS One. 2014 Jun 11;9(6):e99646.
    CrossRef
21. Ryu OH, Lee S, Yu J, Choi MG, Yoo HJ, Mantero F. A prospective randomized controlled trial of the effects of vitamin D supplementation on long-term glycemic control in type 2 diabetes mellitus of Korea. Endocr J. 2014;61(2):167-76.
    CrossRef
22. Leonardo M. Bella, Isis Fieri, Fernando H. G. Tessaro, Eduardo L. Nolasco, Fernanda P. B. Nunes, Sabrina S. Ferreira, Carolina B. Azevedo, Joilson O. Martins. Vitamin D Modulates Hematological Parameters and Cell Migration into Peritoneal and Pulmonary Cavities in Alloxan-Diabetic Mice. BioMed Research International Volume 20, Article ID 76518, 10 pages https://doi.org/10.1155/2017/7651815
    CrossRef
23. Govind Mehar, Rajesh Asija. Relation of liver diseases in type II diabetes patients: an overview. Journal of Drug Discovery and Therapeutics Volume 3, Issue 27, 2015, 10-14
24. İlker Boyraz, Uğur Bilge, Murat Ünalacak, Muzaffer Bilgin.A comparison of 25(OH) vitamin D levels in patients with type 2 diabetes on oral hypoglycemic agents and insulin treatment. Biomedical Research 2016; 27 (1): 1-5
25. Alam U, Amjad Y, Chan AW, Asghar O, Petropoulos IN, Malik RA. Vitamin D Deficiency Is Not Associated with Diabetic Retinopathy or Maculopathy. J Diabetes Res. 2016;2016:6156217.
    CrossRef
26. Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6.
    CrossRef
27. Lim S, Kim MJ, Choi SH, Shin CS, Park KS, Jang HC, Billings LK, Meigs JB. Association of vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian subjects. Am J Clin Nutr. 2013 Mar;97(3):524-30.
    CrossRef
28. Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011 Nov;158(5):276-81.
    CrossRef
29. John E. Hall. Guyton and Hall Textbook of Medical Physiology 13^th Ed Elsevier 2016 Ch 80 pg 1014
30. Cimbek A, Gürsoy G, Kirnap NG, Acar Y, Kiliç Z, Güngör F, Ozaşik I. Relation of obesity with serum 25 hydroxy vitamin D3 levels in type 2 diabetic patients. J Res Med Sci. 2012 Dec;17(12):1119-23.
31. Krul-Poel YH, Agca R, Lips P, van Wijland H, Stam F, Simsek S. Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2015 Jul 16;14:89.
    CrossRef

(Visited 232 times, 1 visits today)